ProLynx Inc.-preview

Prolynxinc

ProLynx Inc.

Private

San Francisco, CaliforniaHealthcare & Life Scienceshttps://prolynxinc.com

Last Round

Series A

Dec 11, 2025

Total Funding Raised

$72.65M

Momentum Score

50 /100

Company Overview

ProLynx Inc. is a biotechnology company developing ultra-long-acting medicines for obesity and related metabolic diseases using its proprietary half-life extension technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

half-life extensiondrug delivery platformlong-acting therapeuticsself-cleaving linkerscontrolled releaseonce-monthly semaglutidelong-acting injectablesprodrug developmentobesity treatmentmetabolic disease treatmentbiotech licensingextended-release formulationoncologyhydrogel microspheres

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ProLynx Inc. Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ProLynx Inc. Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Dec 11, 2025
Seed	Sep 10, 2020
Grant	Jul 7, 2020
Debt	Apr 14, 2020
Grant	Nov 1, 2018
Grant	Sep 25, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Chris Boulton

Chief Executive Officer

Executive Team

ProLynx Inc. Investors

Notable investors and investment history

Investor	Rounds
NIH RADx	Grant
OrbiMed	Series A
5AM Ventures	Series A
Monograph Capital	Series A
National Science Foundation	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Dec 11, 2025
Secured $70 million to fund a weight-loss drug pipeline.
Dec 11, 2025
$70M round completed.

View all signals

ProLynx Inc. Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

ProLynx Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ProLynx Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California

Employee Range30

Year Founded2009

Last FundingDec 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.